08:09 EST Kura Oncology (KURA) drops 11% to $8.07 after leukemia update, BTIG downgrade
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Scotiabank would buy Kura on weakness despite KOMET-001 uncertainty
- Kura Oncology downgraded to Neutral from Buy at BTIG
- Kura Oncology price target raised to $40 from $37 at H.C. Wainwright
- Closing Bell Movers: Semis down sharply after results
- Kura, Kyowa Kirin announce KOMET-001 results, FDA feedback for trial designs